High-tech firms are built much more on the intellectual capital of key personnel than on physical assets, and firms built around the best scientists are most likely to be successful in commercializing breakthrough technologies. As a result, such firms are expected to have higher market values than similar firms less well endowed. In this paper we develop and implement an option-pricing based technique for valuing these and similar intangible assets by examining the effect of ties to star scientists on the market value of new biotech firms. Since firms with more star ties are likely to have a greater probability per unit time of making a commercially valurable R&D breakthrough, we argue and confirm empirically that both the value of the firm and the likelihood of jumps in the value are increasing in the number of star ties. These effects can be financially as well as statistically significant: for two firms with mean values for other variables, the predicted increase in market value of a firm with one article written by a star as or with a firm employee is 7.3% or 16 million 1984 dollars compared to a firm with no articles.
Section 3 in the text and the Data Appendix include detailed information about the data sources and how we organize our sample. All nominal variables in this list have been converted into 1984 US dollars by using CPI . When we calculated the firm's total debt level, we also included the debt-like liabilities. This solves the problem that some biotech companies never issue debts. When we calculated R&D stock, we only considered the R&D expenditures since the firm went public (we don't have R&D information before the firm went public). So our calculation biases downwardly the size of the firm's R&D stock. As a remedy to this problem, we also use R&D expenditures in certain year as the proxy for intangible assets. Note also that we choose 15% as the depreciation rate of R&D investment because most researchers think this as a reasonable level (see Jaffe (1986) 
Estimation of Implicit Parameters Using R&D Expenditures Instead of R&D Stock
One challenge to our study is to find the appropriate proxy for the firm's intangible assets. In Table 3 , we use R&D stock as the proxy. R&D stock may be a noisy measure of the firm's intangible assets. Some researchers have used R&D expenditures directly as the measure of intangible assets. In this table, we use R&D expenditure (in 1984 US dollars) to proxy intangible assets, S. The estimation results are reported below. The shadow price of intangible assets, β, has increased from 0.8 to 1.8. The magnitude of increase is consistent with findings of other researchers. (See Hall (1999) 
Sensitivity Analysis of the effects of Ties on the Firm's Market Valuation
In this table, we calculate the model values for firms with different sizes. We then calculate how the firm's model value increases with the increase of the firm-specific intellectual human capital measure, ties. We choose the firms which are 25 th percentile, 50 th percentile, 75 th percentile, 90 th percentile and also the firm which takes industry mean values for its total asset, R&D stock, debt level and maturity. Here, we assume that the short run risk free interest rate is 6%. Based on our model, the contribution of star scientist to the firm's market value depends on the size of the firm. If the star scientists are tied to larger firms, they would bring more value to the firms. All variables are in millions. 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 year 
